Factors influencing success: Secondary cytoreductive surgery in the management of recurrent ovarian cancer
Abstract
Objective: Secondary cytoreductive surgery (SCRS) plays a key role in the treatment of ROC. The aim of this study was to provide an in-depth analysis of the practical application of SCRS in the management of recurrent ovarian cancer (ROC) and to assess the specific impact of its therapeutic effect on the long-term prognosis of patients. Methods: We collected clinicopathologic data on 83 ROC patients who received SCRS from January 2010 to January 2020, including patient age, histological type, and SCRS results. Kaplan-Meier survival curve, Logistic regression test and Cox proportional risk model were used for univariate regression analysis. Results: We ended up with a detailed analysis of 80 patients. During the observation period, up to the prescribed end of follow-up, 26 patients were observed to be alive, while 57 patients had died. The mean survival of all patients was 56 months. The clinical factors affecting progression-free survival were neoadjuvant chemotherapy [HR (95% CI) = 1.40 (1.13–1.74)], The recurrence interval [HR (95% CI) = 0.51 (0.36–0.70)], previously used chemotherapy line number [HR (95% CI) = 1.46 (1.17–1.82)], recurrence period to the total number of cycles of chemotherapy [HR (95% CI) = 3.48 (2.65–4.57)]. Factors affecting the degree of SCRS completion include tumor stage [HR (95% CI) = 2.723(1.281–5.786)], tumor size [HR (95% CI) = 0.386 (0.153–0.896)], The number of tumors [HR (95% CI) = 2.893 (1.056–7.925)]. Conclusion: Tumor stage, time interval of recurrence, size and number of lesions are closely related to the success rate of SCRS. Recurrent ovarian cancer patients achieve complete elimination of tumor cells through SCRS to optimize treatment outcomes and prognosis.
References
1. Baek MH, Park EY, Ha HI, Park SY, Lim MC, Fotopoulou C, Bristow RE. Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis. J Clin Oncol. 2022 May 20;40(15):1659-1670. doi: 10.1200/JCO.21.02085. Epub 2022 Feb 21. PMID: 35188810.
2. Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A; DESKTOP III Investigators. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294. Erratum in: N Engl J Med. 2022 Feb 17;386(7):704. doi: 10.1056/NEJMx220002. PMID: 34874631.
3. De Bree E, Michelakis D, Anagnostopoulou E. The current role of secondary cytoreductive surgery for recurrent ovarian cancer. Front Oncol. 2022 Oct 21;12:1029976. doi: 10.3389/fonc.2022.1029976. PMID: 36338689; PMCID: PMC9633943.
4. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O’Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21. PMID: 28438473; PMCID: PMC5715461.
5. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. PMID: 31722153; PMCID: PMC6941470.
6. Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S, Cosentino F, Scambia G. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. doi: 10.1136/ijgc-2020-001640. Epub 2020 Oct 7. PMID: 33028623.
7. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618. PMID: 29342393.
8. Goldberg RM, Kim SR, Fazelzad R, Li X, Brown TJ, May T. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 2022 Jan;164(1):212-220. doi: 10.1016/j.ygyno.2021.10.080. Epub 2021 Oct 28. PMID: 34756470.
9. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014 May;10(5):261-75. doi: 10.1038/nrendo.2013.255. Epub 2013 Dec 24. PMID: 24366116.
10. Jiang C, Li Z. Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer. Front Oncol. 2021 Sep 23;11:674637. doi: 10.3389/fonc.2021.674637. PMID: 34631517; PMCID: PMC8496933.
11. Antonio CCP, Alida GG, Elena GG, Rocío GS, Jerónimo MG, Luis ARJ, Aníbal ND, Francisco BV, Jesús GRÁ, Pablo RR, José GM. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Ann Surg Oncol. 2022 Apr;29(4):2617-2625. doi: 10.1245/s10434-021-11087-7. Epub 2021 Nov 23. PMID: 34812982.
12. Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 2023 Oct;24(10):1109-1118. doi: 10.1016/S1470-2045(23)00396-0. Epub 2023 Sep 11. PMID: 37708912.
13. Son JH, Lee J, Yum SH, Kim J, Kong TW, Chang SJ, Ryu HS. Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer. Cancers (Basel). 2022 Aug 18;14(16):3987. doi: 10.3390/cancers14163987. PMID: 36010977; PMCID: PMC9406724.
14. Sharp R, Cummings M, Fielder A, Mikocka-Walus A, Grech C, Esterman A. The catheter to vein ratio and rates of symptomatic venous thromboembolism in patients with a peripherally inserted central catheter (PICC): a prospective cohort study. Int J Nurs Stud. 2015 Mar;52(3):677-85. doi: 10.1016/j.ijnurstu.2014.12.002. Epub 2014 Dec 19. PMID: 25593110.
15. Jennifer A, Iptissem N, Aurélie R, Philippe K, Marc AJ. The place of secondary complete cytoreductive surgery in advanced ovarian cancer. Horm Mol Biol Clin Investig. 2019 Nov 29;41(3). doi: 10.1515/hmbci-2019-0030. PMID: 31782948.
16. Cosentino F, Turco LC, Fagotti A, Cianci S, Gallotta V, Rosati A, Corbisiero F, Scambia G, Ferrandina G. Arterial-enteric fistula after pelvic lymphadenectomy in secondary cytoreductive surgery for recurrent ovarian cancer. J Obstet Gynaecol. 2019 Nov;39(8):1049-1056. doi: 10.1080/01443615.2019.1586856. Epub 2019 Jun 14. PMID: 31195870.
17. Zang R, Zhu J. Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer? J Gynecol Oncol. 2019 Nov;30(6):e116. doi: 10.3802/jgo.2019.30.e116. PMID: 31576701; PMCID: PMC6779624.
18. Van Stein RM, Aalbers AGJ, Sonke GS, van Driel WJ. Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review. JAMA Oncol. 2021 Aug 1;7(8):1231-1238. doi: 10.1001/jamaoncol.2021.0580. PMID: 33956063.
19. Harrison R, Zighelboim I, Cloven NG, Marcus JZ, Coleman RL, Karam A. Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement. Gynecol Oncol. 2021 Dec;163(3):448-452. doi: 10.1016/j.ygyno.2021.10.008. Epub 2021 Oct 20. PMID: 34686355.
20. Bickell NA, Egorova N, Prasad-Hayes M, Franco R, Howell EA, Wisnivesky J, Deb P. Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer. Am J Clin Oncol. 2018 May;41(5):458-464. doi: 10.1097/COC.0000000000000310. PMID: 27391357; PMCID: PMC5665721.
21. Praiss AM, Zhou Q, Iasonos A, Moukarzel L, Dessources K, Soldan K, Su K, Sonoda Y, Roche KL, Gardner GJ, Troso-Sandoval T, Tew WP, Grisham RN, Chi DS, O’Cearbhaill RE, Zivanovic O. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial. Gynecol Oncol. 2023 Apr;171:23-30. doi: 10.1016/j.ygyno.2023.02.003. Epub 2023 Feb 16. PMID: 36804618; PMCID: PMC10206782.
22. Climent MT, Serra A, Llueca M, Llueca A. Surgery in Recurrent Ovarian Cancer: A Meta-Analysis. Cancers (Basel). 2023 Jul 2;15(13):3470. doi: 10.3390/cancers15133470. PMID: 37444580; PMCID: PMC10340282.
23. Gasparri ML, Grandi G, Bolla D, Gloor B, Imboden S, Panici PB, Mueller MD, Papadia A. Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. J Cancer Res Clin Oncol. 2016 Jul;142(7):1509-20. doi: 10.1007/s00432-015-2090-3. Epub 2015 Dec 11. PMID: 26660323.
24. Yabuno A, Hasegawa K. [Ⅰ. Secondary Cytoreductive Surgery for Platinum-Sensitive Recurrent Ovarian Cancer -Review and Consideration from Recent International Phase Ⅲ Trials]. Gan To Kagaku Ryoho. 2021 Feb;48(2):191-194. Japanese. PMID: 33597357.
25. Cianci S, Ronsini C, Vizzielli G, Tropea A, Biondi A, Scambia G, Fagotti A. Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence. Updates Surg. 2019 Jun;71(2):389-394. doi: 10.1007/s13304-018-0600-y. Epub 2018 Nov 8. PMID: 30406932.
26. Marchetti C, Fagotti A, Scambia G, De Felice F. ASO Author Reflections: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer. Ann Surg Oncol. 2021 Jun;28(6):3264-3265. doi: 10.1245/s10434-020-09260-5. Epub 2020 Oct 29. PMID: 33123859.
27. Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O’Malley DM, Wright AA. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol. 2019 Dec;221(6):625.e1-625.e14. doi: 10.1016/j.ajog.2019.06.009. Epub 2019 Jun 14. PMID: 31207237.
Copyright (c) 2024 Huixing Yi, Rongdong Zeng, Xiaogang Lv
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright on all articles published in this journal is retained by the author(s), while the author(s) grant the publisher as the original publisher to publish the article.
Articles published in this journal are licensed under a Creative Commons Attribution 4.0 International, which means they can be shared, adapted and distributed provided that the original published version is cited.
Submit a Paper
